{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T18:48:15Z","timestamp":1778006895832,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41409-019-0673-3","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T12:02:50Z","timestamp":1568635370000},"page":"224-232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study"],"prefix":"10.1038","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7454-7824","authenticated-orcid":false,"given":"Katie S.","family":"Gatwood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Socie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Milpied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lioure","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Mailhol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"673_CR1","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.bbmt.2018.04.008","volume":"24","author":"S Sengsayadeth","year":"2018","unstructured":"Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, et al. Transplant outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biol Blood Marrow Transplant. 2018;24:1406\u201314.","journal-title":"Biol Blood Marrow Transplant"},{"key":"673_CR2","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.2147\/OTT.S101333","volume":"11","author":"L Fianchi","year":"2018","unstructured":"Fianchi L, Criscuolo M, Fabiani E, Falconi G, Maraglino AME, Voso MT, et al. Therapy-related myeloid neoplasms: clinical perspectives. Onco Targets Ther. 2018;11:5909\u201315.","journal-title":"Onco Targets Ther"},{"key":"673_CR3","doi-asserted-by":"crossref","unstructured":"Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS. Acute myeloid leukemia: the good, the bad, and the ugly. Am Soc Clin Oncol Educ Book. 2018;38:555\u201373.","DOI":"10.1200\/EDBK_199519"},{"key":"673_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11864-015-0355-3","volume":"16","author":"SB Zeichner","year":"2015","unstructured":"Zeichner SB, Arellano ML. Secondary adult acute myeloid leukemia: a review of our evolving understanding of a complex disease process. Curr Treat Options Oncol. 2015;16:37.","journal-title":"Curr Treat Options Oncol"},{"key":"673_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1053\/j.seminoncol.2013.09.013","volume":"40","author":"S Bhatia","year":"2013","unstructured":"Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol. 2013;40:666\u201375.","journal-title":"Semin Oncol"},{"key":"673_CR6","doi-asserted-by":"publisher","first-page":"85937","DOI":"10.18632\/oncotarget.13262","volume":"7","author":"S Bertoli","year":"2016","unstructured":"Bertoli S, Sterin A, Tavitian S, Oberic L, Ysebaert L, Bouabdallah R, et al. Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. Oncotarget. 2016;7:85937\u201347.","journal-title":"Oncotarget"},{"key":"673_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cam4.799","volume":"6","author":"R Kotchetkov","year":"2017","unstructured":"Kotchetkov R, Masih-Khan E, Chu CM, Atenafu EG, Chen C, Kukreti V, et al. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed\/refractory multiple myeloma patients. Cancer Med. 2017;6:3\u201311.","journal-title":"Cancer Med"},{"key":"673_CR8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/10428194.2016.1217527","volume":"58","author":"JJ Castillo","year":"2017","unstructured":"Castillo JJ, Gertz MA. Secondary malignancies in patients with multiple myeloma, Waldenstrom macroglobulinemia and monoclonal gammopathy of undetermined significance. Leuk Lymphoma. 2017;58:773\u201380.","journal-title":"Leuk Lymphoma"},{"key":"673_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"673_CR10","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"673_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204\u201317.","journal-title":"Am J Med"},{"key":"673_CR12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610\u20131.","journal-title":"Bone Marrow Transplant"},{"key":"673_CR13","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#","volume":"18","author":"PK Andersen","year":"1999","unstructured":"Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489\u20131500.","journal-title":"Stat Med"},{"key":"673_CR14","doi-asserted-by":"crossref","unstructured":"Sengsayadeth S, Savani BN, Blaise D, Mohty M. Selecting optimal conditioning regimen and stem cell source. Semin Hematol. 2016;2:111\u20134.","DOI":"10.1053\/j.seminhematol.2016.01.012"},{"key":"673_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3324\/haematol.2015.123331","volume":"100","author":"S Sengsayadeth","year":"2015","unstructured":"Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohty M. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission\u2014a review from the Acute Leukemia Working Party of the EBMT. Haematologica. 2015;100:859\u201369.","journal-title":"Haematologica"},{"key":"673_CR16","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/bloodadvances.2018019976","volume":"2","author":"S Sengsayadeth","year":"2018","unstructured":"Sengsayadeth S, Gatwood KS, Boumendil A, Labopin M, Finke J, Ganser A, et al. Conditioning intensity in secondary AML with prior myelodysplastic syndrome\/myeloproliferative disorders: an EBMT ALWP study. Blood Adv. 2018;2:2127\u201335.","journal-title":"Blood Adv"},{"key":"673_CR17","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154\u201361.","journal-title":"J Clin Oncol"},{"key":"673_CR18","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","volume":"29","author":"RJ van Kampen","year":"2011","unstructured":"van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011;29:1342\u20138.","journal-title":"J Clin Oncol"},{"key":"673_CR19","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1182\/blood.V80.8.2142.2142","volume":"80","author":"JM Vose","year":"1992","unstructured":"Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J, et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood. 1992;80:2142\u20138.","journal-title":"Blood"},{"key":"673_CR20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00277-011-1395-9","volume":"91","author":"L Rigacci","year":"2012","unstructured":"Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S, et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol. 2012;91:931\u20139.","journal-title":"Ann Hematol"},{"issue":"4","key":"673_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/joim.12870","volume":"285","author":"F. Baron","year":"2019","unstructured":"Baron F, Labopin M, Ruggeri A, Volt F, Mohty M, Blaise D, et al. Cord blood transplantation is associated with good outcomes in secondary acute myeloid leukemia in first remission. J Intern Med. 2018. \nhttps:\/\/doi.org\/10.1111\/joim.12870","journal-title":"Journal of Internal Medicine"},{"key":"673_CR22","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1182\/bloodadvances.2018020206","volume":"2","author":"GW Roloff","year":"2018","unstructured":"Roloff GW, Griffiths EA. When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter. Blood Adv. 2018;2:3070\u201380.","journal-title":"Blood Adv"},{"key":"673_CR23","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.bbmt.2017.01.084","volume":"23","author":"RB Salit","year":"2017","unstructured":"Salit RB, Oliver DC, Delaney C, Sorror ML, Milano F. Prognostic value of the hematopoietic cell transplantation comorbidity index for patients undergoing reduced-intensity conditioning cord blood transplantation. Biol Blood Marrow Transplant. 2017;23:654\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"673_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.bbmt.2018.11.030","volume":"25","author":"Mahmoud Elsawy","year":"2019","unstructured":"Elsawy M, Storer BE, Milano F, Sandmaier BM, Delaney C, Salit RB, et al. Prognostic performance of the augmented hematopoietic cell transplantation-specific comorbidity\/age index in recipients of allogeneic hematopoietic stem cell transplantation from alternative graft sources. Biol Blood Marrow Transplant. 2018. \nhttps:\/\/doi.org\/10.1016\/j.bbmt.2018.11.030","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"6","key":"673_CR25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41409-018-0344-9","volume":"54","author":"Piyanuch Kongtim","year":"2018","unstructured":"Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, et al. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2018. \nhttps:\/\/doi.org\/10.1038\/s41409-018-0344-9","journal-title":"Bone Marrow Transplantation"},{"issue":"6","key":"673_CR26","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3324\/haematol.2018.204826","volume":"104","author":"Fr\u00e9d\u00e9ric Baron","year":"2018","unstructured":"Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, et al. Impact of induction regimen and of allogeneic hematopoietic cell transplantation on outcome in younger adults patients with acute myeloid leukemia with a monosomal karyotype. Haematologica. 2018. \nhttps:\/\/doi.org\/10.3324\/haematol.2018.204826","journal-title":"Haematologica"},{"key":"673_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.beha.2018.09.002","volume":"31","author":"JM Rowe","year":"2018","unstructured":"Rowe JM. Progress and predictions: AML in 2018. Best Pr Res Clin Haematol. 2018;31:337\u201340.","journal-title":"Best Pr Res Clin Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0673-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:15:43Z","timestamp":1684617343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0673-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["673"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0673-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]},"assertion":[{"value":"14 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}